TIGIT inhibitors, such as tibolumab, vibostolimab, ocperlimab, M-6223, ASP-8374, COM-902 and IBI-939, have been under clinical trials in patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC) and gastric adenocarcinoma (GAC). The gene discussed is TIGIT; the disease is esophageal squamous cell carcinoma.